復星醫藥(02196.HK)發行1.06億新A股 集資44.84億人民幣
復星醫藥(02196.HK)公佈,向10名投資者非公開發行總計1.06億股新A股,每股作價42元人民幣,集資總額約44.84億人民幣。所得淨額擬用作投入創新藥物臨牀、許可引進及產品上市相關準備;原料藥及製劑集約化綜合性基地;及補充流動資金。
完成後,控股股東復星國際(00656.HK)於公司持股將由目前39.63%攤薄至38.04%,視作出售收益約10.85億人民幣,爲股東權益的增加,不會影響復星國際的溢利或虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.